Optimizing Infliximab Treatment for Inflammatory Bowel Disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on improving the treatment of inflammatory bowel disease (IBD) by using infliximab, a monoclonal antibody that targets tumor necrosis factor. It aims to monitor and optimize infliximab dosing through a dashboard-guided approach, which considers individual patient factors and laboratory parameters. The study will involve adult inpatients with moderate-to-severe IBD who have not responded to intravenous corticosteroids and require infliximab therapy. By tailoring the treatment based on therapeutic drug monitoring, the researchers hope to enhance patient outcomes and reduce the incidence of treatment failure.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult inpatients with Crohn's disease, ulcerative colitis or inflammatory bowel disease-unclassified.
* Moderate-to-severe flare who fail to iv steroids and require infliximab as per standard of care by treating gastroenterologist

Exclusion Criteria:

* Participant younger than 18 years
* Non-controlled infectious diseases
* Permanent ileostomy or Ileal pouch-anal anastomosis
* Pregnancy
* Patients do not consent to participate in study
* Patients unable to comply with protocol

Where it's running

• Pontificia Universidad Catolica of Chile
  Santiago, Chile Recruiting

Study contacts

• Study coordinator: Cristian Hernández-Rocha Cristian Hernández-Rocha, MD
• Email: caherna4@uc.cl
• Phone: 56-22-3543838

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Wearable data to spot IBD flareups in people with ulcerative colitis or Crohn's disease

  This study tests whether heart‑rate variability from participants’ own wearables can help predict IBD flares.

  Recruiting at 2 sites Maastricht University Medical Center · 's-Hertogenbosch and 2 other locations · NCT07647640

• Switching to guselkumab for adults with active IBD after ustekinumab

  We will try guselkumab (Tremfya) in adults with active IBD whose symptoms didn't improve enough on ustekinumab.

  Recruiting at 12 sites TIDHI Innovation Inc. · Calgary, Alberta and 13 other locations · NCT07245394

• Zymfentra (infliximab-dyyb) real-world cohort

  This project will see if Zymfentra (infliximab-dyyb) reduces symptoms over one year in adults with Crohn's disease, ulcerative colitis, or indeterminate colitis who are starting or switching to the drug as part of routine care.

  Recruiting at 11 sites University of North Carolina, Chapel Hill · New Haven, Connecticut and 10 other locations · NCT07237516

• Reducing ultra-processed foods in children and teens with IBD

  This project will test whether short nutrition handouts or handouts plus a brief video can help children and teens with IBD eat fewer ultra-processed foods.

  Recruiting Connecticut Children's Medical Center · Hartford, Connecticut · NCT07224113

• SMART-IBD app for teens with inflammatory bowel disease

  This will test whether the SMART-IBD smartphone app helps adolescents ages 13–17 with IBD take their medicines and manage symptoms better than completing daily diaries alone.

  Recruiting Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio · NCT07195123

• TIDHI Healing Circuits mental health program for people with IBD

  This study tests whether Healing Circuits™ delivered by a social worker or via a self-guided online program helps adults with IBD who have moderate anxiety or depression.

  Recruiting TIDHI Innovation Inc. · North York, Ontario · NCT07013578

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.